NAMI website: “The safest way to treat severe depression in a pregnant woman is probably electroconvulsive (ECT) therapy. Patients and families are sometimes frightened by the idea of ‘shock treatment,’ but in fact ECT is safer than antidepressant medication for a depressed pregnant woman. It can be used during any state of pregnancy, but is less risky after the first trimester.”
Already, the explosive growth in online advertising has intensified public concerns: the pharmaceutical industry spent more than $1 billion on Internet ads last year and is projected to spend $1.7 billion on such marketing efforts in 2012…
Grassley’s investigation shows the National Alliance on Mental Illness has received more than $28 million from pharmaceutical companies in the last four years. However, that number doesn’t include pharmaceutical contributions given to NAMI’s 50 state chapters or related foundations. Grassley is now demanding that information, according to documents obtained by Dow Jones Newswires. But more than conflict of interests are at stake.
Bipartisan legislation sponsored by Grassley to require drug, device and biologic manufacturers to report quarterly to the Department of Health and Human Services payments to physicians is part of the health care reform bill passed by the Senate Committee on Finance. The Physician Payments Sunshine Act, S.301, would establish the first-ever nationwide requirement for this information to be reported and made publicly available.
That suit alleges that Pfizer turned NAMI into a “Trojan Horse” to promote the antipsychotic drug Geodon for off-label use in children, according to the former pharmaceutical sales rep who filed it.